A look back at pembrolizumab for lung cancer that spread to the brain
Original title: Real-world effectiveness and safety of pembrolizumab monotherapy in non-small-cell lung carcinoma with brain metastases.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This drug is already approved and given to patients today.
The short version
Doctors reviewed 25 patients who took this drug, and some tumors shrank.
What was studied. Doctors at one hospital in Spain looked back at patient records from August 2017 to March 2023. They found 25 adults with advanced lung cancer that had spread to the brain. All of them took the drug pembrolizumab on its own.
What they found. Tumors shrank in 24% of the patients. In 40%, the cancer stayed under control for a time. A typical patient lived about 6 months, and the cancer held steady for about 3 months. Side effects from the drug showed up in 64% of patients, and doctors saw no surprising safety problems.
What this means, and what it doesn't
What it could mean: This drug is already approved and used in regular care. The study suggests it can help some people whose lung cancer has spread to the brain. The side effects were the ones doctors already expect.
What it doesn't mean: This does not mean the drug works for most people. It was a look back at records for only 25 patients at a single hospital. That kind of study is much weaker than a planned trial. The authors say larger studies are still needed to learn who it helps. Living time was still short, and this is not a cure.
Source: PubMed, November 3, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.